The USPSTF lowered the screening start age to 45 in 2021. Five years later, many GI practices still have not realigned their scheduling model or their patient financial communication to match the changed demand.
Key Takeaways
- The 2021 USPSTF update lowered the recommended screening start age to 45, with a Grade B recommendation for ages 45 to 49 and Grade A for ages 50 to 75 – both requiring zero patient cost-sharing under ACA-compliant plans.
- Medicare covers screening colonoscopy at no cost sharing for average-risk beneficiaries every 10 years, but the diagnostic coding trap – when a polyp is removed during a scheduled screening – can generate unexpected patient liability that causes downstream cancellations and complaints.
- The CY 2026 Medicare conversion factor of $33.4209 applies to colonoscopy professional fees; diagnostic colonoscopy (45378) generates roughly $169 in the physician office setting, and the distinction between screening and diagnostic drives both payment and patient out-of-pocket exposure.
- Scheduling capacity for screening colonoscopy is a demand-management problem, not just a calendar problem: the bottleneck is usually prep instruction quality and pre-procedure communication, not room availability.
In May 2021, the U.S. Preventive Services Task Force updated its colorectal cancer screening recommendation to include average-risk adults beginning at age 45, down from the prior threshold of 50. The task force gave ages 50 to 75 a Grade A recommendation and ages 45 to 49 a Grade B – both grades requiring zero patient cost-sharing under ACA-compliant commercial health plans. That policy change added roughly 19 million Americans to the eligible screening population overnight. Five years later, the demand is real and growing, and many GI practices have not rebuilt their scheduling infrastructure to handle it.
The clinical implication is straightforward. The business implication requires more attention. A colonoscopy performed under a screening indication at a zero-cost-sharing benefit is a different financial event than the same procedure performed under a diagnostic indication, and the difference is paid by the patient – sometimes unexpectedly, sometimes after the fact, always badly. Getting this right requires the front desk to know the difference before the patient checks in, the scheduling system to capture the correct indication, and the billing team to code it accurately. All three of those things fail in the average GI practice at a rate that produces real patient dissatisfaction and real write-offs.
The Coverage Rules, Stated Plainly
Under Medicare, screening colonoscopy for average-risk beneficiaries is covered every ten years with no deductible, no coinsurance, and no copay. High-risk beneficiaries – those with a personal or family history of colorectal cancer or adenomas – are covered every two years under the same zero-cost-sharing terms. A follow-up colonoscopy after a positive non-invasive screening test (such as a positive FIT or stool DNA test) is covered as a screening benefit, also without cost sharing, under a rule CMS clarified in 2023.
For commercial payers with ACA-compliant plans, the USPSTF Grade A and B recommendations for colorectal cancer screening require the plan to cover the service without cost sharing. This applies to all USPSTF-recommended modalities: colonoscopy, FIT, stool DNA testing, CT colonography, and flexible sigmoidoscopy. The operative phrase is ACA-compliant – grandfathered plans and some self-insured employer plans that pre-date the ACA may not carry the same mandate, and some states have coverage rules that vary from the federal floor. Verify benefit at the individual plan level rather than assuming compliance by payer name.
The screening-to-diagnostic conversion happens when a polyp is removed. The patient who came in expecting a zero-dollar visit leaves with a bill. How you communicate that in advance determines whether they come back.
The Polyp Trap and How to Handle It
The most consequential billing nuance in GI practice is the one that affects the most patients who came in believing their colonoscopy was free. When a polyp is found and removed during a scheduled screening colonoscopy, the procedure changes from a preventive screening to a therapeutic intervention under Medicare coding rules. The claim is billed with the appropriate therapeutic CPT code – typically 45385 for snare polypectomy – and the deductible and coinsurance that apply to therapeutic services may be triggered.
Congress amended this rule for Medicare beneficiaries through the Consolidated Appropriations Act of 2023, phasing in a reduction in patient cost-sharing for therapeutic colonoscopies that begin as screenings over several years. The phase-in runs through 2030, gradually reducing what the patient owes when a screening becomes therapeutic. That is meaningful relief but it is not zero – patients still owe a share, and that share needs to be communicated before the procedure, not on the explanation of benefits three weeks later.
For commercial payers, the rule varies by plan and state. Some plans apply zero cost-sharing to the entire encounter when it begins as a screening regardless of what is found; others apply the deductible as soon as a therapeutic code is billed. Your billing team needs a payer-by-payer matrix, updated annually during contract renewal review, and your scheduling staff needs a scripted pre-procedure communication that sets accurate expectations without frightening patients into canceling.
Coding Accuracy and the Preventive-to-Diagnostic Cascade
Beyond the polyp removal issue, coding accuracy for colonoscopy indication determines reimbursement in ways that compound over time. A practice that habitually upcodes screening procedures as diagnostic – capturing a higher physician payment at the cost of patient cost-sharing – is building a patient satisfaction and compliance problem. A practice that downcodes therapeutic procedures as screening – trying to protect patients from cost-sharing exposure – is building a billing compliance problem. Neither is a sound operating choice.
The correct approach is accurate coding by indication, supported by documentation in the procedure note that reflects the clinical picture, paired with proactive patient financial communication that addresses the scenarios most likely to generate surprise bills. The front desk conversation at scheduling is the right moment for that communication, not the back-office billing cycle. Staff who can explain the polyp scenario in plain language before the appointment – and who can tell a patient what their estimated out-of-pocket would be if a polyp is found – turn a potential complaint into a satisfied patient who comes back for surveillance.
Scheduling Capacity and Demand Management
The expansion of screening eligibility to age 45 has raised demand for colonoscopy without proportionally expanding the supply of endoscopy room time, GI physician capacity, or anesthesia availability. In most markets, the bottleneck is not the calendar – it is the conversion rate from referral to completed procedure.
GI practices with access problems routinely find on analysis that a meaningful share of their scheduling gap is driven by three correctable factors: inadequate prep instruction that leads to failed preps and repeated procedures, pre-procedure phone call volumes that overload MA staff and delay confirmation, and cancellation rates driven by patient cost-sharing surprise that could have been addressed at scheduling. None of those are capacity problems in the physical sense. They are process problems, and they are fixable without adding rooms or physicians.
From the Field
A three-physician GI practice in the South had an eight-week wait for screening colonoscopy and a cancellation rate that the practice manager estimated at around 18 percent of confirmed appointments. The group assumed it needed more room time. An operational review found that about half the cancellations were driven by two things: patients who called after receiving an explanation of benefits from a prior visit and were confused about what the upcoming procedure would cost, and patients who received prep instructions by mail with no follow-up call and either misread them or received them too late. Rather than hand over a process manual, our fractional COO engagement rebuilt the pre-procedure communication workflow with the MA team: scripted the scheduling conversation to include a plain-language cost estimate, shifted prep instructions to a documented call at seven days pre-procedure, and added a two-day-out confirmation with a direct callback number. Cancellation rate fell to just under 9 percent over the following quarter on the same room capacity. The wait time dropped to five weeks without a single new room.
Consulting vs. Execution on This Problem
The analysis above – coding accuracy review, payer matrix construction, scheduling workflow redesign – can be delivered by a competent consultant in a focused engagement, and if your practice has a strong manager or billing coordinator who can implement the recommendations, that scope may be exactly right. We will tell you honestly if that is the case.
What we see more often is that the scheduling and coding issues persist not because nobody has identified them, but because the MA who would change the scripts is already at capacity, the billing coordinator who would build the payer matrix is working a 90-day AR backlog, and the practice manager who would oversee both is also handling credentialing and HR. The work requires someone to sit inside the scheduling workflow and the billing system, not to deliver a guide to doing it. A fractional executive stays through implementation – not as a consultant handing off a plan, but as someone working in your systems alongside your staff until the numbers change. Verify before you hire which of those you are actually buying, because the label “fractional executive” is unregulated and the two services are not the same.
Sources
- U.S. Preventive Services Task Force, Final Recommendation Statement: Colorectal Cancer Screening (2021) — https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/colorectal-cancer-screening
- CMS, CY 2026 Hospital Outpatient Prospective Payment System and ASC Payment System Final Rule — https://www.cms.gov/medicare/payment/prospective-payment-systems/ambulatory-surgical-center-asc/asc-payment-rates-addenda
- American Gastroenterological Association, CMS Finalizes Payment Policies for 2026 (November 2025) — https://gastro.org/news/cms-finalizes-payment-policies-for-2026/
- American College of Gastroenterology, Significant Impacts to GI in Medicare Physician Fee Schedule Proposed Rule (July 2025) — https://gi.org/2025/07/29/significant-impacts-to-gi-in-medicare-physician-fee-schedule-proposed-rule/
More in the Gastroenterology Series
- Endoscopy Center Economics: What GI Groups Need to Know Before They Build or Buy — the financial case for ASC ownership and the numbers to model before you commit.
- GI Ancillary Services: Pathology, Anesthesia, and Infusion – What Works and What Gets You Audited — how to structure pathology, anesthesia, and infusion revenue without creating compliance exposure.
- Advanced Practice Providers in Gastroenterology: Deploying NPs and PAs Without Losing Money — how to build an APP model in GI that actually covers its own cost and expands physician capacity.
- GI Payer Contracting and Evaluating Consolidation Offers: A Decision Framework for Independent Practices — how to negotiate GI payer contracts from a position of strength and evaluate consolidation offers with clear financial criteria.